These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

456 related items for PubMed ID: 31432563

  • 21. Initial results of a drug checking pilot program to detect fentanyl adulteration in a Canadian setting.
    Tupper KW, McCrae K, Garber I, Lysyshyn M, Wood E.
    Drug Alcohol Depend; 2018 Sep 01; 190():242-245. PubMed ID: 30064061
    [Abstract] [Full Text] [Related]

  • 22. Stakeholder perspectives on implementing fentanyl drug checking: Results from a multi-site study.
    Glick JL, Christensen T, Park JN, McKenzie M, Green TC, Sherman SG.
    Drug Alcohol Depend; 2019 Jan 01; 194():527-532. PubMed ID: 30551090
    [Abstract] [Full Text] [Related]

  • 23. Acceptability of implementing community-based drug checking services for people who use drugs in three United States cities: Baltimore, Boston and Providence.
    Sherman SG, Morales KB, Park JN, McKenzie M, Marshall BDL, Green TC.
    Int J Drug Policy; 2019 Jun 01; 68():46-53. PubMed ID: 30991301
    [Abstract] [Full Text] [Related]

  • 24. Beyond a spec: assessing heterogeneity in the unregulated opioid supply.
    Gozdzialski L, Louw R, Kielty C, Margolese A, Poarch E, Sherman M, Cameron F, Gill C, Wallace B, Hore D.
    Harm Reduct J; 2024 Mar 15; 21(1):63. PubMed ID: 38491435
    [Abstract] [Full Text] [Related]

  • 25. Fiber spray ionization mass spectrometry in forensic chemistry: A screening of drugs of abuse and direct determination of cocaine in urine.
    Filho JFA, Dos Santos NA, Borges KB, Lacerda V, Pelição FS, Romão W.
    Rapid Commun Mass Spectrom; 2020 Sep 15; 34 Suppl 3():e8747. PubMed ID: 32056289
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. How do we understand the value of drug checking as a component of harm reduction services? A qualitative exploration of client and provider perspectives.
    Moran L, Ondocsin J, Outram S, Ciccarone D, Werb D, Holm N, Arnold EA.
    Harm Reduct J; 2024 May 11; 21(1):92. PubMed ID: 38734643
    [Abstract] [Full Text] [Related]

  • 28. Data-independent screening method for 14 fentanyl analogs in whole blood and oral fluid using LC-QTOF-MS.
    Palmquist KB, Swortwood MJ.
    Forensic Sci Int; 2019 Apr 11; 297():189-197. PubMed ID: 30802648
    [Abstract] [Full Text] [Related]

  • 29. Identification of three unexpected new psychoactive substances at an Australian drug checking service.
    Algar JL, Lawes DJ, Carroll AJ, Caldicott D, McLeod MD.
    Drug Test Anal; 2024 Oct 11; 16(10):1144-1154. PubMed ID: 38205685
    [Abstract] [Full Text] [Related]

  • 30. Losing the uphill battle? Emergent harm reduction interventions and barriers during the opioid overdose crisis in Canada.
    Strike C, Watson TM.
    Int J Drug Policy; 2019 Sep 11; 71():178-182. PubMed ID: 30975595
    [Abstract] [Full Text] [Related]

  • 31. High concentrations of illicit stimulants and cutting agents cause false positives on fentanyl test strips.
    Lockwood TE, Vervoordt A, Lieberman M.
    Harm Reduct J; 2021 Mar 09; 18(1):30. PubMed ID: 33750405
    [Abstract] [Full Text] [Related]

  • 32. A qualitative assessment of key considerations for drug checking service implementation.
    Grace Rose C, Pickard AS, Kulbokas V, Hoferka S, Friedman K, Epstein J, Lee TA.
    Harm Reduct J; 2023 Oct 17; 20(1):151. PubMed ID: 37848875
    [Abstract] [Full Text] [Related]

  • 33. Drug checking to detect fentanyl and new psychoactive substances.
    Palamar JJ, Salomone A, Barratt MJ.
    Curr Opin Psychiatry; 2020 Jul 17; 33(4):301-305. PubMed ID: 32187173
    [Abstract] [Full Text] [Related]

  • 34. PS2MS: A Deep Learning-Based Prediction System for Identifying New Psychoactive Substances Using Mass Spectrometry.
    Lin YC, Chien WC, Wang YX, Wang YH, Yang FS, Tseng LP, Hung JH.
    Anal Chem; 2024 Mar 26; 96(12):4835-4844. PubMed ID: 38488022
    [Abstract] [Full Text] [Related]

  • 35. "It wasn't here, and now it is. It's everywhere": fentanyl's rising presence in Oregon's drug supply.
    Shin SS, LaForge K, Stack E, Pope J, Leichtling G, Larsen JE, Leahy JM, Seaman A, Hoover D, Chisholm L, Blazes C, Baker R, Byers M, Branson K, Korthuis PT.
    Harm Reduct J; 2022 Jul 11; 19(1):76. PubMed ID: 35818072
    [Abstract] [Full Text] [Related]

  • 36. Xylazine detected in unregulated opioids and drug administration equipment in Toronto, Canada: clinical and social implications.
    Bowles JM, McDonald K, Maghsoudi N, Thompson H, Stefan C, Beriault DR, Delaney S, Wong E, Werb D.
    Harm Reduct J; 2021 Oct 13; 18(1):104. PubMed ID: 34645480
    [Abstract] [Full Text] [Related]

  • 37. Expanding harm reduction to include fentanyl urine testing: results from a pilot in rural British Columbia.
    Mema SC, Sage C, Popoff S, Bridgeman J, Taylor D, Corneil T.
    Harm Reduct J; 2018 Apr 06; 15(1):19. PubMed ID: 29625621
    [Abstract] [Full Text] [Related]

  • 38. Validation of a lateral flow chromatographic immunoassay for the detection of fentanyl in drug samples.
    Park JN, Sherman SG, Sigmund V, Breaud A, Martin K, Clarke WA.
    Drug Alcohol Depend; 2022 Nov 01; 240():109610. PubMed ID: 36115223
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.